Moreover, a clinical study with CeD patients in a GFD, whom either consumed regular or transamidated gliadin (Ethical Committee of San G. Moscati Hospital OsSc registry n.06/09, trial n.234, and Ethical Committee ASL Salerno, OsSc registry n.318; trial n.118/AA.GG), reported significant decreases in clinical relapse, intestinal permeability, anti-transglutaminase IgA levels, Vh/Cd and IFN-γ expression in the group with transamidated gliadin intake [253]. This evidence concerns the gene IFNG and cranioectodermal dysplasia.